NCT03968302View on ClinicalTrials.gov

ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

PHASE2CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

May 15, 2019

Study Completion Date

May 15, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

ARM A Triple therapy for helicobacter pylori

The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.

DRUG

ARM B Quadruple therapy for helicobacter pylori

Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.

Trial Locations (1)

Unknown

Ziauddin University Hospital, Karachi

All Listed Sponsors
lead

Ziauddin University

OTHER

NCT03968302 - ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION | Biotech Hunter | Biotech Hunter